Abstract
Prion diseases are characterized biochemically by protein aggregation of infectious prion isoforms (PrPSc), which result from the conformational conversion of physiological prion proteins (PrPC). PrPC are variable post-translationally modified glycoproteins, which exist as full length and as aminoterminally truncated glycosylated proteins and which exhibit differential detergent solubility. This implicates the presence of heterogeneous phenotypes, which overlap as protein complexes at the same molecular masses. Although the biological function of PrPC is still enigmatic, evidence reveals that PrPC exhibits metal-binding properties, which result in structural changes and decreased solubility. In this study, we analyzed the yield of PrPC metal binding affiliated with low solubility and changes in protein banding patterns. By implementing a high-speed centrifugation step, the interaction of zinc ions with PrPC was shown to generate large quantities of proteins with low solubility, consisting mainly of full-length glycosylated PrPC; whereas unglycosylated PrPC remained in the supernatants as well as truncated glycosylated proteins which lack of octarepeat sequence necessary for metal binding. This effect was considerably lower when PrPC interacted with copper ions; the presence of other metals tested exhibited no effect under these conditions. The binding of zinc and copper to PrPC demonstrated differentially soluble protein yields within distinct PrPC subtypes. PrPC–Zn2+-interaction may provide a means to differentiate glycosylated and unglycosylated subtypes and offers detailed analysis of metal-bound and metal-free protein conversion assays.
Introduction
Prion diseases are fatal neurodegenerative disorders characterized clinically by a long incubation period followed by a rapid course of disease, and biochemically by the accumulation of the infectious prion protein PrPSc. PrPSc originates from a host encoded prion protein (PrPC) by conformational conversion. As the mechanism of the folding of PrPSc is not yet clear, the conversion is associated with dramatic changes in biochemical and biophysical properties. PrPC is sensitive to proteolysis, is completely hydrolysed, and has high α-helix content [1]; whereas PrPSc demonstrates an increase of β-sheet structures [2] leading to hydrophobicity, the formation of fibrillar depositions and partial protease resistance. Following expression, PrPC is post-translationally modified by the formation of a glycophosphatidyl-inositol (GPI) anchor and a disulphide bond. Glycans attach to one or two asparagine residues yielding in di-, mono- and unglycosylated proteins [3].
PrPC proteins are characterized by heterogeneous phenotypes in distinct brain regions and display several subtypes, which overlap distinct protein patterns identified by means of differential detergent solubility [4–5]. The differential glycoprotein pattern observed may be a result of distinct biological functions such as synaptic transmissions, transport processes and metal binding, indicating an involvement in neuroprotective and oxidative stress reactions [6–9]. PrPC is known to be a metalloprotein having the capability of binding multiple zinc and copper ions that stimulate the endocytosis of PrP. Additionally, the protein is thought to be associated with metal-dependent enzymatic functions and with copper homeostasis [10–15]. A highly conserved octarepeat region is located within the aminoterminal region containing identical repeats (PHGGGWGQ) that were shown to have a high affinity for copper [16]. For each of the histidine residues within the octarepeats, one copper ion can be bound with a higher affinity than other divalent ions [17–18]. Both copper and zinc binding impart conformational changes in the structure of PrP demonstrated by the formation of protease resistance and protein insolubility [19–20]. Additional, full-length PrPC can be truncated at the aminoterminus under physiological conditions generating a glycosylated C1 fragment which is present in brains in substantial amounts [21].
The post-translational modifications themselves and the structural changes due to metal ion interactions increase the variability of PrPC proteins. It is not known whether the modifications, the impact of metal binding or both are essential for the development of prion diseases. In comparison to the incidence of various existing PrPC types expressed in normal tissue and brain, very few PrPSc types have been identified in diseased species. This suggests that different PrPC isoforms may vary in their potential for conformational conversion. To reduce the conversion efficiency to PrPSc, it is important to first identify and target PrPC subtypes with a high-yield conversion. In this study, we performed metal-binding analyses on phenotypes of heterogeneous brain PrPC isoforms derived from uninfected humans, bovine, sheep and mice in order to identify protein subtypes with either high or low solubility. Our results reveal that PrPC markedly exhibited a lower solubility when zinc was bound to the protein, whereas copper binding showed little effect on solubility. Differential solubility as a result of metal binding offers a new tool to examine PrPC isoforms bound to protein complexes.
Materials and Methods
Antibodies
Monoclonal anti-PrP antibodies (mabs) SAF34 and SAF70 were prepared by immunizing knock-out mice with formic acid-denatured, hamster scrapie-associated fibrils (263K) [22]. Mab SAF34 recognizes an epitope in the octarepeats detecting the aminoterminal sequence, whereas mab SAF70 binds to the core protein at amino acids 156–162. The antibodies in this study were applied as ascitic fluids obtained from mice and originated from one slot. The brain marker neuron specific enolase (NSE) was used as a control protein detected by using a monoclonal mouse anti-NSE antibody, which was purchased as a purified IgG antibody (Dianova, Hamburg, Germany).
Brain tissue
Brain tissue was obtained from TSE-free humans, sheep, bovine and mice. Human brain tissue derived from five individuals was pooled from several unspecified sample regions and comprised mostly of cortex and cerebellum. All experiments on human subjects were conducted in accordance with the Declaration of Helsinki and all procedures were carried out with the adequate understanding and written consent of the subjects. Brain tissue samples were obtained from the Brain Bank, Institute of Neuropathology at the University Hospital Münster [4]. Consent for autopsy and scientific examination was obtained from the legal representatives (Ethics Committee of the Westphalia Chamber of Physicians and the Faculty of Medicine, University of Münster) for all subjects in accordance with the local institutional review board. The bovine and sheep brain samples were provided from the Chemische und Veterinäruntersuchungsamt Münsterland—Emscher—Lippe after routine analyses for TSE and slaughtering processes in slaugtherhouses in Northrhine Westfalia, Germany, and homogenates were prepared from different brain areas in four biological replicates. Mouse brain tissue was obtained from C57BL wild-type mice and T182N transgenic mice, which are characterized by a deletion of the glycosylation site at codon 182 via an amino acid exchange from asparagine (N) to threonine (T) [23]. Animal experiments were approved, and their implementation supervised by the competent authorities of the Federal State of Mecklenburg-Western-Pomerania, according to the German Animal Welfare Act. The experiments in mice described in this manuscript were approved by the competent authority of the Federal State of Baden-Wuerttemberg, Germany on the basis of national and European legislation, namely the EU council directive 86/609/EEC for the protection of animals used for experiments (Regierungspräsidium Tübingen BFAV-Tierversuchsvorhaben Nr. 156—Herstellung und Charakterisierung transgener Mauslinien mit gewebespezifischer Expression des Prionproteins oder der Expression artifizieller Prionproteine). Breeding occurred at the Federal Research Centre for Virus Diseases of Animals, Tübingen, Germany, according to the rules and conditions listed above. Mice obtained from the mouse breeding facility of the Friedrich-Loeffler Institute were fed ad libitum with commercial mouse feed and were euthanized by carbon dioxide intoxication. Animals were kept in Macrolon cages (type 2 long; groups of maximum 5 mice respectively) in rooms in which a natural day/night light cycle regime was run, and they were controlled daily for their clinical status. Four whole brains from both wild-type and transgenic mice were pooled separately for homogenization.
Homogenate preparations
Brain tissues were weighed and suspended in nine volumes of Tris buffered saline (TBS; pH 7.4) in order to prepare 10% (w/v) homogenates followed by the application of 2% N-octyl-β-D-glucopyranoside (OGP). Electric homogenizers were used for consistent homogenization followed by intensive ultrasonication as described [5]. Samples were stored at -20°C until use, and experiments were carried out with one charge of a pooled homogenate under standardized conditions.
Addition of divalent cations, SDS and EDTA
Divalent cations such as CuCl2, ZnCl2, MnCl2, MgCl2, NiSO4, CaCl2, and CoCl2 (Sigma, Taufkirchen, Germany), each at a concentration of 1 mM or otherwise indicated, were added to the samples and incubated at room temperature for 30–60 min. To separate cellular prion protein fractions of high and low solubility, homogenates were centrifuged at 16,000 × g for 10 min resulting in supernatants and pellets. Pellets were washed with TBS to remove residual supernatant proteins and were resuspended in SDS-loading buffer.
To demonstrate the metal binding to PrPC, samples were incubated with the metal chelator ethylene diamine tetraacetic acid (EDTA; Serva, Heidelberg, Germany) or with sodium dodecylsulphate (SDS) in indicated concentrations at room temperature for 30 min, followed by centrifugation as described.
Enzymatic treatment of protein samples
The enzyme bromelain was purchased from Sigma-Aldrich (Taufkirchen, Germany) as a chromatographically purified protease from pineapple stem. Protein suspensions from brain were treated enzymatically with bromelain at 37°C with gentle agitation using a concentration of 50 µg/ml for 60 min. Proteolysis was terminated by heating at 99°C for 10 min.
Immunoblot analysis
Samples resuspended in SDS-loading buffer were denatured at 99°C for 5 min. Proteins were separated using sodium dodecyl sulphate polyacrylamide (13%) gel electrophoresis (SDS-PAGE) in a mini slab gel apparatus (Bio-Rad, Munich, Germany). After electrotransfer onto polyvinylidene difluoride (PVDF) membranes (Immobilon-P; Roth, Karlsruhe, Germany) using a semi-dry blotting system (Roth, Germany), non- specific binding was blocked on membranes by incubation in TBS containing 0.05% Tween 20 (TBST) and 1% (w/v) non-fat dry milk powder for 1 h at room temperature. Specific detection of PrPC was accomplished by incubating the membranes with the antibodies indicated at room temperature over night. Membranes were washed with TBST prior to incubation with peroxidase-conjugated goat anti-mouse immunoglobulin antibodies (Dianova, Hamburg, Germany) as secondary antibody for 2 h at room temperature. After washing with TBST PrPC bands were visualized using a chemiluminescence enhancement kit (Thermo Scientific, Bonn, Germany).
Results
Metal-binding to PrPC results in a decrease of protein solubility
Homogenized brain tissue suspensions from human, bovine, sheep and mouse were treated with the detergent N-octyl-β-D-glucopyranoside (OGP), which is non-ionic, and does not denature proteins. After centrifugation, the highly soluble proteins in the supernatants were exposed to various metal ions prior to incubation. Although we exclusively used proteins with high solubility, the binding of zinc to PrPC induced a considerable shift of proteins into a PrPC isoform of low solubility retrievable in the pellet after high-speed centrifugation (Fig 1). The incubation of PrPC with copper ions clearly had a much lower effect on decreasing the solubility of PrPC under these conditions; the levels of PrPC with low solubility were only marginally higher than those observed in the presence of Co2+ and Ni2+. PrPC remained highly soluble in the presence of Ca2+, Mg2+ and Mn2+ ions as well as in the absence of metals.
To verify a zinc specific effect, mouse PrPC was incubated with increasing concentrations of the zinc ion (Fig 2). We found that ZnCl2 reduced PrPC solubility at concentrations as low as 50 to 100 µM, and insolubility rose as Zn2+ concentrations were increased. With respect to the protein profile in the pellet fraction, the full length diglycosylated isoforms dominated, whereas the truncated glycosylated C1 proteins and the unglycosylated isoforms exhibited lower intensities. Zn2+ bound PrPC was determined by using the monoclonal antibody SAF34 that recognizes an epitope within the octarepeats (Fig 2A). To analyze whether this banding profile originated from an antibody specific effect, we examined protein profiles by binding mab SAF70 to the core protein region (Fig 2B). Interestingly, two different banding patterns with Zn2+ interaction were revealed. In the supernatants, a dominant band was observed, which consisted of highly soluble PrPC having a molecular mass of unglycosylated PrPC. This protein signal resulted from an overlay of unglycosylated PrPC and truncated glycosylated C1 protein, because both isoforms had the same electrophoretic mobility. Unglycosylated PrPC demonstrated lower signal intensity than truncated glycosylated C1 protein shown by protein deglycosylation using N-glycosidase F treatment (data not shown). In contrast, low PrPC signals were observed for the full-length glycosylated isoforms. In the pellets, however, high signals were detected for the full-length diglycosylated PrPC band; these intensified as Zn2+ concentrations were increased. This result indicated that binding of Zn2+ to PrPC is directly correlated to the solubility reduction of the full-length diglycosylated form of PrPC. This differential solubility effect as a result of Zn2+-PrPC interaction was not observed with Cu2+ and Mg2+ under the same conditions and specificity was demonstrated by using the neuron specific enolase (NSE) as a control protein, which remained highly soluble within the range of Zn2+concentration used (Fig 2C).
Glycosylated PrPC isoforms interact with zinc to lower the solubility of proteins
To analyze the influence of the glycosylation grade on the increase of pelleted PrPC-Zn2+ we added metal ions to wild-type mouse brain homogenates featuring two glycosylation sites, which can be modified at one or both sites and to mouse homogenates of the transgenic mouse line T182N characterized by one deleted glycosylation site [22] (Fig 3). In immunoblots the monoglycosylated band was observed as a strong signal, whereas the signal at the molecular mass of the unglycosylated PrPC was hardly visible. Additionally, an unknown fragment derived from the carboxy terminus was detected at approximately 22 kDa.
High signal intensities of full-length diglycosylated wild-type PrPC bound to Zn2+ were detected in the pellet fraction, whereas glycosylated C1 fragment and unglycosylated PrPC was abundant in the supernatant (Fig 3). In contrast, very faint signals of all PrPC isoforms were observed in the pellet with copper interaction and no signals were detected with manganese and calcium or as well as in the absence of metals. PrPC derived from transgenic mice T182N exhibited a lower solubility than fully glycosylated wild-type PrPC. However, Zn2+ triggered a decrease in the solubility of the full-length glycosylated isoform in proteins from both T182N as well as wild-type mice. This finding indicates that zinc binding results in an important structural change in glycosylated PrPC. Under these conditions, a weak yet visible effect was also seen with Cu2+. The unknown 22 kDa fragment of T182N was always detected in the highly soluble fraction.
Decreases in PrPC solubility as a result of metal binding is a reversible process
The effect of PrPC interaction with zinc, which results in a decrease in solubility, was reversible by treatment with ethylene diamine tetraacetic acid (EDTA) and sodium dodecylsulphate (SDS) (Fig 4). Mouse and bovine homogenates pre-incubated with zinc or copper ions were treated with the metal chelator EDTA. EDTA at equimolar and higher concentrations reversed PrPC from low to high solubility. Reversibility was determined using the amino terminal region-binding antibody SAF34 and the core region-binding antibody SAF70 as well (not shown). High solubility of zinc and copper-bound PrPC was also induced by treatment with the protein denaturing detergent sodium dodecylsulphate (SDS).
Truncation of the PrPC amino-terminus prior to metal binding prevented the shift to low solubility
Metal ions bind within the octarepeats at histidine residues with high affinity, whereas zinc binds with lower affinity [18;24]. To verify that the PrPC-Zn2+ phenotype is the result of metal binding to the octarepeats, we partially truncated the full-length protein by enzymatic treatment with bromelain obtained from Ananas comosus. The amino-terminal region was cleaved off, whereas a stable core protein consisting of glycosylated and nonglycosylated isoforms was generated (Fig 5). Removal of the amino-terminus prior to incubation in the presence of metals prevented PrPC from changing to low solubility. This result indicates an interaction of Zn2+ with the N-terminal region of PrPC.
PrPC solubility by combined and serial metal incubations
In the next series of experiments, we analysed the solubility of PrPC following combined and serial incubations with copper and zinc ions (Fig 6). The Zn2+-PrPC-phenotype predominated, even following simultaneous incubation with both copper and zinc ions in identical concentrations (Fig 6A). The three isoforms—un-, mono- and diglycosylated PrPC—were abundant in the pellet fraction when using mab SAF34 as a detection antibody. The full-length diglycosylated PrPC from wild-type mice and the full-length monoglycosylated derived from the mutant T182N mice showed high signal intensity in the pellet, whereas the truncated glycosylated C1 fragment and the unglycosylated wild-type PrPC isoforms dominated the supernatant when using mab SAF70. This Zn2+-PrPC-phenotype persisted as well in samples that had been treated serially with different metal ions (Fig 6B). Using the antibodies mab SAF34 and mab SAF70, an increase in the abundance of copper loaded PrPC was observed in the pellets after Zn2+ ions had been independently added to the proteins. Collectively, zinc binding to PrPC had an important influence on decreasing the solubility of PrPC, whereas copper binding failed to neutralize the Zn2+-PrPC-phenotype. This suggests an additional metal-protein interaction and a different biochemical characteristic independent of the copper-PrPC interactions.
Discussion
Although the biological functions of PrPC remain an enigma, it is known that PrPC interacts with several metal ions such as Cu2+, Zn2+, Mn2+, Pd2+, Pt2+ and Co2+ when sufficient concentrations are present [25–30]; these metallochemical changes might facilitate protein conversion leading to the development of prion diseases [31]. The binding of Zn2+ and Cu2+ are accompanied by structural changes and decreased solubility [19–20]. However, the effect of metal binding as a means of protein differentiation has not yet been analyzed. In the present study, we distinguished PrPC isoforms using high-speed centrifugation in conjunction with metal binding. The interaction of zinc with PrPC induced an important shift from high to low protein solubility, mainly affecting the full-length glycosylated isoforms. Although both metals bound to the amino-terminal region, copper binding did not reveal the structural changes affiliated with low solubility under these conditions. Copper binds to histidine residues via the octarepeats and to single sites outside this region with high efficiency with a Kd of 6.7 to 14 µM [16–18;24;32–33]. Zinc interacts with a lower affinity than copper, and the Kd was determined as approximately 200 µM [29].
The interaction between PrP proteins seems to be mediated by copper and zinc binding within the amino-terminal region of PrP [34], which could influence differential solubility. It is conceivable that Cu2+ acts as a bridge between PrP proteins [35–36]. Such interactions are promoted by copper and zinc [37], with Zn2+ having a greater influence on these interactions than Cu2+. This Zn2+ induced PrP-PrP interaction may have decreased protein solubility concurrent with the level of Zn2+ bound PrP that we observed in the pellet fraction. Copper ions seem to be unable to stimulate PrP interactions with the efficiency of Zn2+.
In conclusion, PrPC differentiation based on metal binding provides a technique capable of distinguishing PrPC isoforms bound within protein complexes. This may also enable the separation of full-length glycosylated and full-length nonglycosylated as well as truncated glycosylated isoforms, due to the decreased solubility of Zn2+ bound full-length glycosylated PrPC in comparison to truncated PrP. Zn2+ selectively bound to full-length PrPC but not to truncated and nonglycosylated PrPC attributed to lack of the octarepeat sequence in the C1 fragment. As various PrP isoforms coexist in homogenized solutions, the separation of metal-bound and unbound PrPC proteins based on different conformation and aggregation types can easily be accomplished by incorporating a high-speed centrifugation step.
Acknowledgments
We thank Jacques Grassi from the Commissariat à l’Energie Atomique, Service de Pharmacologie et d’Immunoanalyse, CEA/Saclay, France, for supplying the antibodies SAF34 and SAF70, the Institute for Neuropathology at the Westfälische Wilhelms-University Münster for providing human brain samples and the Chemisches und Veterinäruntersuchungsamt Münsterland–Emscher–Lippe for proving bovine and sheep brain samples. We gratefully thank Olga Böhler for her excellent technical assistance.
Data Availability
All relevant data are within the paper.
Funding Statement
The authors have no support or funding to report.
References
- 1.Gasset M, Baldwin MA, Fletterick RJ, Prusiner SB. Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. Proc Natl Acad Sci USA. 1993;90: 1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA. 1993;90: 10962–10966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Stahl N, Baldwin MA, Burlingame AL, Prusiner SB. Identification of glycoinositol phospholipid linked and truncated forms of the scrapie prion protein. Biochemistry. 1990;29: 8879–8884. [DOI] [PubMed] [Google Scholar]
- 4.Kuczius T, Koch R, Keyvani K, Karch H, Grassi J, Groschup MH. Regional and phenotype heterogeneity of cellular prion proteins in the human brain. Eur J Neurosci. 2007;25: 2649–2655. [DOI] [PubMed] [Google Scholar]
- 5.Kuczius T, Wohlers J, Karch H, Groschup MH. Subtyping of human cellular prion proteins and their differential solubility. Exp Neurol. 2011;227: 188–194. 10.1016/j.expneurol.2010.10.014 [DOI] [PubMed] [Google Scholar]
- 6.Brown DR, Schulz-Schaeffer WJ, Schmidt B, Kretzschmar HA. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp Neurol. 1997;146: 104–112. [DOI] [PubMed] [Google Scholar]
- 7.Hu W, Kieseier B, Frohman E, Eagar TN, Rosenberg RN, Hartung HP, et al. Prion proteins: physiological functions and role in neurological disorders. J Neurol Sci. 2008;264: 1–8. [DOI] [PubMed] [Google Scholar]
- 8.Lasmézas CI. Putative functions of PrP(C). Br Med Bull. 2003;66: 61–70. [DOI] [PubMed] [Google Scholar]
- 9.Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, et al. Signal transduction through prion protein. Science 2000;289: 1925–1928. [DOI] [PubMed] [Google Scholar]
- 10.Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ, Jones IM. Normal prion protein has an activity like that of superoxide dismutase. Biochem J. 1999;344: 1–5. [PMC free article] [PubMed] [Google Scholar]
- 11.Brown LR, Harris DA. Copper and zinc cause delivery of the prion protein from the plasma membrane to a subset of early endosomes and the Golgi. J Neurochem. 2003;87: 353–363. [DOI] [PubMed] [Google Scholar]
- 12.Estibeiro JP. Multiple roles for PrP in the prion diseases. Trends Neurosci. 1996;19: 257–258. [DOI] [PubMed] [Google Scholar]
- 13.Pauly PC, Harris DA. Copper stimulates endocytosis of the prion protein. J Biol Chem. 1998;273: 33107–33110. [DOI] [PubMed] [Google Scholar]
- 14.Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278: 245–251. [DOI] [PubMed] [Google Scholar]
- 15.Rachidi W, Vilette D, Guiraud P, Arlotto M, Riondel J, Laude H, et al. Expression of prion protein increases cellular copper binding and antioxidant enzyme activities but not copper delivery. J Biol Chem. 2003;278: 9064–9072. [DOI] [PubMed] [Google Scholar]
- 16.Stöckel J, Safar J, Wallace AC, Cohen FE, Prusiner SB. Prion protein selectively binds copper(II) ions. Biochemistry. 1998;37: 7185–7193. [DOI] [PubMed] [Google Scholar]
- 17.Hornshaw MP, McDermott JR, Candy JM. Copper binding to the N-terminal tandem repeat regions of mammalian and avian prion protein. Biochem Biophys Res Commun. 1995;207: 621–629. [DOI] [PubMed] [Google Scholar]
- 18.Viles JH, Cohen FE, Prusiner SB, Goodin DB, Wright PE, Dyson HJ. Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proc Natl Acad Sci USA. 1999;96: 2042–2047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Qin K, Yang DS, Yang Y, Chishti MA, Meng LJ, Kretzschmar HA, et al. Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. J Biol Chem. 2000;275: 19121–19131. [DOI] [PubMed] [Google Scholar]
- 20.Quaglio E, Chiesa R, Harris DA. Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform. J Biol Chem.2001;276: 11432–11438. [DOI] [PubMed] [Google Scholar]
- 21.Chen SG, Teplow DB, Parchi P, Teller JK, Gambetti P, Autilio-Gambetti LJ. Truncated forms of the human prion protein in normal brain and in prion diseases. Biol Chem. 1995;270: 19173–19180. [DOI] [PubMed] [Google Scholar]
- 22.Demart S, Fournier JG, Creminon C, Frobert Y, Lamoury F, Marce D, et al. New insight into abnormal prion protein using monoclonal antibodies. Biochem Biophys Res Commun. 1999;265: 652–657. [DOI] [PubMed] [Google Scholar]
- 23.Neuendorf E, Weber A, Saalmueller A, Schatzl H, Reifenberg K, Pfaff E, et al. Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections. J Biol Chem. 2004;279: 53306–53316. [DOI] [PubMed] [Google Scholar]
- 24.Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, et al. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106–126. Biochemistry. 2001;40: 8073–8084. [DOI] [PubMed] [Google Scholar]
- 25.Gaggelli E, Bernardi F, Molteni E, Pogni R, Valensin D, Valensin G, et al. Interaction of the human prion PrP(106–126) sequence with copper(II), manganese(II), and zinc(II): NMR and EPR studies. J Am Chem Soc. 2005;127: 996–1006. [DOI] [PubMed] [Google Scholar]
- 26.Garnett AP, Jones CE, Viles JH. A survey of diamagnetic probes for copper2+ binding to the prion protein. 1H NMR solution structure of the palladium2+ bound single octarepeat. Dalton Trans. 2006;21: 509–518. [DOI] [PubMed] [Google Scholar]
- 27.Pushie MJ, Rauk A, Jirik FR, Vogel HJ. Can copper binding to the prion protein generate a misfolded form of the protein? Biometals. 2009;22: 159–175. 10.1007/s10534-008-9196-x [DOI] [PubMed] [Google Scholar]
- 28.Pushie MJ, Ross AR, Vogel HJ. Mass spectrometric determination of the coordination geometry of potential copper(II) surrogates for the mammalian prion protein octarepeat region. Anal Chem. 2007;79: 5659–5667. [DOI] [PubMed] [Google Scholar]
- 29.Walter ED, Stevens DJ, Visconte MP, Millhauser GL. The prion protein is a combined zinc and copper binding protein: Zn2+ alters the distribution of Cu2+ coordination modes. J Am Chem Soc. 2007;129: 15440–15441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zhu F, Davies P, Thompsett AR, Kelly SM, Tranter GE, Hecht L, et al. Raman optical activity and circular dichroism reveal dramatic differences in the influence of divalent copper and manganese ions on prion protein folding. Biochemistry. 2008;47: 2510–2517. 10.1021/bi7022893 [DOI] [PubMed] [Google Scholar]
- 31.Bush AI. Metals and neuroscience. Curr Opin Chem Biol. 2000;4: 184–191. [DOI] [PubMed] [Google Scholar]
- 32.Watanabe Y, Hiraoka W, Igarashi M, Ito K, Shimoyama Y, Horiuchi M, et al. A novel copper(II) coordination at His186 in full-length murine prion protein. Biochem Biophys Res Commun. 2010;394: 522–528. 10.1016/j.bbrc.2010.03.003 [DOI] [PubMed] [Google Scholar]
- 33.Whittal RM, Ball HL, Cohen FE, Burlingame AL, Prusiner SB, Baldwin MA. Copper binding to octarepeat peptides of the prion protein monitored by mass spectrometry. Protein Sci. 2000;9: 332–343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Leliveld SR, Dame RT, Wuite GJ, Stitz L, Korth C. The expanded octarepeat domain selectively binds prions and disrupts homomeric prion protein interactions. J Biol Chem. 2006;281: 3268–3275. [DOI] [PubMed] [Google Scholar]
- 35.Gonzalez-Iglesias R, Elvira G, Rodriguez-Navarro JA, Velez M, Calero M, Pajares MA, et al. Cu2+ binding triggers R BoPrP assembly into insoluble laminar polymers. FEBS Lett. 2004;556: 161–166. [DOI] [PubMed] [Google Scholar]
- 36.Morante S, Gonzalez-Iglesias R, Potrich C, Meneghini C, Meyer-Klaucke W, Menestrina G, et al. Inter and intra-octarepeat Cu(II) site geometries in the prion protein: Implications in Cu(II) binding cooperativity and Cu(II)-mediated assemblies. J Biol Chem. 2004;279: 11753–11759. [DOI] [PubMed] [Google Scholar]
- 37.Kenward AG, Bartolotti LJ, Burns CS. Copper and zinc promote interactions between membrane-anchored peptides of the metal binding domain of the prion protein. Biochemistry. 2007;46: 4261–4271. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All relevant data are within the paper.